Erstellt von fchar99
Akebia Therapeutics Inc. diskutieren
Akebia Therapeutics Inc.
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
1,20 €
0,00 %
Negatives P / E-Verhältnis
Stimmen Sie mit dem Verkaufskonsens überein. Die Märkte wackeln heute nach unten aufgrund der Gewinnbeteiligung, die diesem Lager nicht helfen wird. Lautstärke zu klein.
(Zielkurs erreicht)
Buy Akebia Therapeutics Inc.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $3.75 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.75 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $3.75 to $5.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at HC Wainwright from $5.00 to $6.00. They now have a "buy" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.50 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) had its price target raised by analysts at Piper Sandler from $4.00 to $6.00. They now have an "overweight" rating on the stock.
Ratings data for AKBA provided by MarketBeat
Akebia Therapeutics, Inc. (NASDAQ: AKBA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $6.00 price target on the stock.
Ratings data for AKBA provided by MarketBeat
Neueste Beiträge
Lake_Street_Capital in Benchmark El. Inc. diskutieren